Olcegepant

Chemical structure of Olcegepant

Olcegepant is a calcitonin gene-related peptide receptor antagonist that has been investigated for its potential use in the treatment of migraine. It is a small molecule drug that was developed to block the action of the calcitonin gene-related peptide (CGRP), a neuropeptide that plays a significant role in the pathophysiology of migraine.

Mechanism of Action

Olcegepant works by selectively binding to the CGRP receptor, thereby inhibiting the binding of CGRP. This prevents the vasodilation and neurogenic inflammation associated with migraine attacks. By blocking CGRP, olcegepant aims to reduce the frequency and severity of migraine headaches.

Development and Clinical Trials

Olcegepant was one of the first CGRP receptor antagonists to be developed and tested in clinical trials. Early studies demonstrated its efficacy in reducing migraine symptoms when administered intravenously. However, the development of an oral formulation proved challenging, and as a result, olcegepant did not progress to market.

Pharmacokinetics

Olcegepant is administered intravenously, which limits its use to clinical settings. The drug has a rapid onset of action, which is beneficial for acute migraine treatment. However, its short half-life necessitates frequent dosing, which is a limitation for its practical use.

Comparison with Other CGRP Antagonists

While olcegepant was a pioneering drug in the class of CGRP antagonists, other drugs such as erenumab, fremanezumab, and galcanezumab have since been developed and approved for the prevention of migraine. These newer agents are typically administered subcutaneously and have longer half-lives, making them more suitable for regular use.

Related Pages

• Migraine
• Calcitonin gene-related peptide
• CGRP receptor antagonist
• Erenumab
• Fremanezumab
• Galcanezumab